Biotech

Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine

2021-09-23 21:59 2116

* Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedic...

Happiness Biotech Announced Another Electric Vehicle Transaction of Over $14 Million With Ruili

2021-09-23 20:32 2387

NANPING, China, Sept. 23, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce solutions, and the sales of automobile, today announced that T...

Nanoform Shortlisted For The European Small and Mid-Cap Awards 2021

2021-09-23 20:15 543

HELSINKI, Sept. 23, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has made the shortlist in the `Star of Innovation' category of the 9th annual European Small and Mid-Cap Awards. The nomination is based on Nanoform being a listed com...

Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer

2021-09-23 20:00 504

NEW YORK and HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-powered drug discovery company, today announced the appointment ofNirav Jhaveri as Chief Financial Officer (CFO) to oversee capital markets, investor relations, financial operation...

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

2021-09-23 20:00 458

BOSTON, Sept. 23, 2021 /PRNewswire/ -- BIORCHESTRA is a bio-tech company focused on the identification of novel targets in neurodegenerative diseases using RNA-based therapeutics. To access these novel targets, BIOCHESRTRA has also developed a proprietary nanoparticle formulation to deliver RNA-b...

Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma

2021-09-23 15:23 696

SINGAPORE and Guangzhou, China and LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. Food and Drug Administration (FDA) for its Investigational...

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

2021-09-23 15:00 2115

- Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), a...

The First US World-Class Bioscience Design Corporation Officially Launched

2021-09-23 09:00 680

TAIPEI, Sept. 22, 2021 /PRNewswire/ --  TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience inAsia to the United States. After two years of continuous effort, it has accumulated a series of extensiv...

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

2021-09-23 07:40 626

SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (A...

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

2021-09-23 06:00 977

VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and lice...

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

2021-09-22 20:00 2988

News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...

Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest

2021-09-22 18:56 605

* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...

Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research

2021-09-22 14:45 520

SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...

Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with "Top 100 Innovation CEO" Award

2021-09-22 02:00 598

PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com  ), has been selected by the judges of World Biz Magazine's annual awards to be a recipient of the "Top 100 Innovation CEO – 2021" (https://www.worldbiz...

Origin Agritech and China Agricultural University to Collaborate on Research of Molecular Design of Corn Using CRISPR

2021-09-21 21:36 3684

BEIJING, Sept. 21, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED)  (the "Company" or "Origin"), an agriculture technology company, today announced that it has entered into collaboration agreement with China Agricultural University for the research of molecular design in corn. One of the...

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

2021-09-21 20:00 856

The solution offers superior ease of formulation, potential application versatility,  and more comprehensive immune support compared to probiotics and other immune health ingredients SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune hea...

Long-termism as Investment Philosophy: Healthcare Investor Sangel Capital Expects to See Big Rise in Investment Value

2021-09-21 10:00 1217

SHENZHEN, China, Sept. 20\1, 2021 /PRNewswire/ -- The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based inChina, is poised for strong growth as multiple biotech and pharmaceutical companies backed by Sangel's venture fund...

Novavax to Participate in Fireside Chat at Devex @ UNGA 76

2021-09-21 04:46 5001

GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced thatJohn J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Busin...

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

2021-09-20 22:51 5899

MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...

PharmAbcine to Participate in BIO-Europe 2021

2021-09-20 20:00 611

DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will tak...

12345 ... 21